Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Change in self-reported pain levels in participants microdosing GLP1s

Participants will complete an extensive medical questionnaire every 4 weeks over a 24-week period to monitor self-reported pain levels

Time frame: 6 months

Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s

CBC panel will be analyzed every 12 weeks over a 24-week period, reported in thousands of cells per microliter with the change from baseline reported as percent deviation and compared to normalized range of healthy individuals

Time frame: 6 months

Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s

BMP panel will be analyzed every 12 weeks over a 24-week period, reported in mg/dL with the change from baseline reported as percent deviation and compared to a normalized range of healthy individuals

Time frame: 6 months

Change in mood in participants microdosing GLP1s

Mood will be assessed every 4 weeks over a 24-week period using the SF-36 standardized questionnaire with deviation reported as percent change from baseline

Time frame: 6 months

Change in heart rate variability in participants microdosing GLP1s

Participants will wear health devices with data monitored every 4 weeks over a 24-week period to observe change in heart rate variability, being defined as the variability of a participant's resting heart rate. Variability will be measured as an average deviation from baseline heart rate at each timepoint and reported as percent difference.

Time frame: 6 months

Changes in sleep patterns in participants microdosing GLP1s

Wearable health device data will be monitored over the 24-week period assessing REM vs non-REM sleep and reported as a ratio

Time frame: 6 months

Change in frequency of physical activity in participants microdosing GLP1s

The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in steps taken.

Time frame: 6 months

Change in frequency of physical activity in participants microdosing GLP1s

The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in calories burned.

Time frame: 6 months